Halneuron, a NaV 1.7 sodium channel inhibitor, is being tested for chemotherapy-induced neuropathic pain, offering a potential opioid alternative. Previous trials showed Halneuron significantly ...

WEDNESDAY, Jan. 29, 2025 (HealthDay News) -- Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence review suggests. These patients might ...

Discover new treatments like ART-123 advancing toward approval to prevent long-term nerve damage caused by ...

WEDNESDAY, Jan. 29, 2025 (HealthDay News) -- Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence review suggests.

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

Nearly 41% of patients treated with platinum-based chemo developed nerve pain, as well as just over 38% of those treated with taxanes, results show. Nerve pain was most common in lung cancer ...

Patients might experience weakness, loss of balance and coordination, numbness or tingling WEDNESDAY, Jan. 29, 2025 (HealthDay News) -- Four in every 10 cancer patients treated with chemotherapy ...

Stabbing, burning or tingling pain can be chronic in cancer patients who undergo chemotherapy. A new study found that 4 in 10 patients get persistent and severe nerve pain from the cancer treatment.

“Chemo belly” is a grouping of several side effects of chemotherapy drugs on the gastrointestinal (GI) ... In addition to bloating, gas, discomfort, and abdominal pain, ...